GENF
NEUTRALGenflow Signs CDAs with Animal Health Companies
The biotechnology company has signed confidential disclosure agreements with animal health companies to advance its longevity gene therapy platform.
Genflow Biosciences
1.3000GBX
8.79%
Market Cap
5.90M
Volume
4.04M
62% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
2.18
Day Range
1.1000p - 1.3000p
52 Week Range
0.5500p1.3000p2.3000p
1.3000p
Upcoming Events
January 2026
Conclusion of five-month follow-up period for Dog Aging (GF-1004) study
High Impact Event
GENF
NEUTRALGenflow Biosciences Director Increases Stake
The biotechnology company has announced a director has increased their shareholding in the business.
GENF
NEUTRALGenflow Advances Dog Aging Gene Therapy Trial with No Adverse Effects
The biotechnology company reports progress on its dog aging gene therapy trial, with no adverse effects seen in the treated animals so far.
GENF
GOODGenflow Biosciences Advances Key Programs Towards Clinical Readiness
The biotechnology company is accelerating the clinical readiness of its lead programs, GF-1002 and GF-1004, through key development activities and strategic partnerships.
GENF
NEUTRALGenflow Secures €4M Grant Support for GF-1002 Program
The biotechnology company has secured non-dilutive funding to support the development of its lead gene therapy program.
GENF
NEUTRALGenflow Biosciences Provides Half Year Corporate Update
The biotechnology company provides an update on the progress of its core programs focused on the SIRT6-centenarian gene and its potential to slow aging and delay the onset of age-related diseases.
GENF
NEUTRALGenflow Biosciences Signs Master Services Agreement with CER Groupe
The biotechnology company has signed a master service agreement with a research partner to accelerate its pre-IND gene therapy programs.
GENF
NEUTRALGenflow Biosciences Announces AGM Notice
The biotechnology company has announced the details of its upcoming Annual General Meeting.
GENF
NEUTRALGenflow Biosciences Announces Progress of Key SIRT6 Patent Application in Japan
The biotechnology company announces an important step in the protection of its SIRT6 intellectual property, with the Japanese Patent Office advancing the application to the national examination phase.
GENF
NEUTRALGenflow Biosciences Announces Director Shareholding Change
The biotechnology company has disclosed a change in director shareholding.